DI FEDERICO, ALESSANDRO
DI FEDERICO, ALESSANDRO
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Assegnisti
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma
2021 Di Federico A.; Filippini D.M.; Sperandi F.; Ardizzoni A.; Melotti B.
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
2022 Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G.
Advanced non-small-cell lung cancer: how to manage non-oncogene disease
2022 De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G.
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
2022 Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G.
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
2020 Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A.
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients
2023 De Giglio A.; Deiana C.; Di Federico A.
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
2023 Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A.
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
2023 Scalera S.; Ricciuti B.; Mazzotta M.; Calonaci N.; Alessi J.V.; Cipriani L.; Bon G.; Messina B.; Lamberti G.; Di Federico A.; Pecci F.; Milite S.; Krasniqi E.; Barba M.; Vici P.; Vecchione A.; De Nicola F.; Ciuffreda L.; Goeman F.; Fanciulli M.; Buglioni S.; Pescarmona E.; Sharma B.; Felt K.D.; Lindsay J.; Rodig S.J.; De Maria R.; Caravagna G.; Cappuzzo F.; Ciliberto G.; Awad M.M.; Maugeri-Sacca M.
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A.
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (Hcc) with orbital metastases: A case report
2021 Filippini D.M.; Di Federico A.; Lenzi B.; Nobili E.; Brocchi S.; Malvi D.; Brandi G.
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
2022 Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib
2024 Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F.
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
2022 De Giglio A.; Di Federico A.; Metro G.
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue
2021 Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G.
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
2024 Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Giglio A.
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
2022 Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Francesca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea
Hacking pancreatic cancer: Present and future of personalized medicine
2021 Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Marco M.; Palloni A.; Brandi G.
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
2020 Di Federico A.; Nuvola G.; Sisi M.; Lenzi B.; Nobili E.; Campana D.
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies
2022 Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelsomino F.
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
2021 Rizzo A.; Ricci A.D.; Lanotte L.; Lombardi L.; Di Federico A.; Brandi G.; Gadaleta-Caldarola G.
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma | Di Federico A.; Filippini D.M.; Sperandi F.; Ardizzoni A.; Melotti B. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease | Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.;... Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | - |
Advanced non-small-cell lung cancer: how to manage non-oncogene disease | De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | dic.2022-2-4.pdf |
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials | Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G. | 2022-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma | Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients | De Giglio A.; Deiana C.; Di Federico A. | 2023-01-01 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review | Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A. | 2023-01-01 | LUNG CANCER: TARGETS AND THERAPY | - | 1.01 Articolo in rivista | - |
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma | Scalera S.; Ricciuti B.; Mazzotta M.; Calonaci N.; Alessi J.V.; Cipriani L.; Bon G.; Messina B.; ...Lamberti G.; Di Federico A.; Pecci F.; Milite S.; Krasniqi E.; Barba M.; Vici P.; Vecchione A.; De Nicola F.; Ciuffreda L.; Goeman F.; Fanciulli M.; Buglioni S.; Pescarmona E.; Sharma B.; Felt K.D.; Lindsay J.; Rodig S.J.; De Maria R.; Caravagna G.; Cappuzzo F.; Ciliberto G.; Awad M.M.; Maugeri-Sacca M. | 2023-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience | Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppion...i E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A. | 2020-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (Hcc) with orbital metastases: A case report | Filippini D.M.; Di Federico A.; Lenzi B.; Nobili E.; Brocchi S.; Malvi D.; Brandi G. | 2021-01-01 | ANNALS OF PALLIATIVE MEDICINE | - | 1.01 Articolo in rivista | Critical diagnostic delay.pdf |
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? | Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, An...drea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib | Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F. | 2024-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer | De Giglio A.; Di Federico A.; Metro G. | 2022-01-01 | TRANSLATIONAL LUNG CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue | Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G. | 2021-01-01 | EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | - | 1.01 Articolo in rivista | - |
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) | Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Gi...glio A. | 2024-01-01 | DIAGNOSTICS | - | 1.01 Articolo in rivista | - |
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes | Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Franc...esca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-03472-v2.pdf; cancers-14-03472-s001.zip |
Hacking pancreatic cancer: Present and future of personalized medicine | Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Mar...co M.; Palloni A.; Brandi G. | 2021-01-01 | PHARMACEUTICALS | - | 1.01 Articolo in rivista | Hacking Pancreatic.pdf |
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? | Di Federico A.; Nuvola G.; Sisi M.; Lenzi B.; Nobili E.; Campana D. | 2020-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies | Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelso...mino F. | 2022-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects | Rizzo A.; Ricci A.D.; Lanotte L.; Lombardi L.; Di Federico A.; Brandi G.; Gadaleta-Caldarola G. | 2021-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |